Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant

Multiple Myeloma (MM)

The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients

Haematologica

Mizuno S, Gras L, Baaij LGA, Koster L, D'Souza A, Hari PN, Estrada-Merly N, Saber W, Cowan AJ, Iida M, Okamoto S, Takamatsu H, Kawamura K, Kodera Y, Hamad N, Ko BS, Liam C, Ho KW, Goh AS, Keat TS, Elhaddad AM, Bazarbachi A, Chaudhry BQUN, Alfar R, Bekadja MA, Benakli M, Ortiz CAF, Riva E, Verburgh E, Galeano S, Bass F, Mian H, McCurdy A, Wang FR, Neumann D, Koh MBC, Snowden JA, Schönland S, McLornan DP, Hayden PJ, Balari AMS, Greinix HT, Aljurf M, Atsuta Y, Rondelli D, Niederwieser DW, Garderet L

doi: 10.3324/haematol.2025.288041

Multiple Myeloma (MM)

Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial

Lancet Haematol

Bringhen S, Cani L, Antonioli E, Derudas D, Fazio F, Larocca A, Ronconi S, Cellini C, Falcone AP, Accardi F, Liberati AM, Galieni P, Belotti A, Cafro AM, Ria R, Benevolo G, Vincelli ID, Mannina D, Lotti F, Bruno B, Marasco V, Mazza R, Tosi P, Rivolti E, Boccadoro M, D'Agostino M

doi: 10.1016/S2352-3026(25)00162-0

Multiple Myeloma (MM)

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing

Blood

Schavgoulidze A, Perrot A, Leleu X, Cazaubiel T, Chretien ML, Feugier P, Belhadj K, Manier S, Roussel M, Brechignac S, Orsini Piocelle F, Mohty M, Schiano de Colella JM, Macro M Dr, Adiko D, Dib M, Fontan J, Motard C, Bouscary D, Pascal L, Roland V, Lifermann F, Bakala JA, Montes L, Kennel C, Rey P, Richez V, Keddar F, Frenzel L, Calmettes C, Chaleteix C, Plantier I, Chalayer E, Schmitt A, Roul C, Demarquette H, Cerutti C, Pavageau L, Derrier L, Avet-Loiseau H, Corre J

doi: 10.1182/blood.2025029999

Multiple Myeloma (MM)

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

Blood Cancer J

Souto Filho JTD, Cantadori LO, Crusoe EQ, Hungria V, Maiolino A

doi: 10.1038/s41408-025-01413-7

Multiple Myeloma (MM)

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

Lancet Oncol

Mateos MV, San-Miguel J, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Yoon SS, Iosava G, Fujisaki T, Garg M, Ngo M, Katz EG, Krevvata M, Bolyard K, Carson R, Borgsten F, Dimopoulos MA

doi: 10.1016/S1470-2045(25)00018-X

Multiple Myeloma (MM)

Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

Blood Cancer J

Souto Filho JTD, Cantadori LO, Crusoe EQ, Hungria V, Maiolino A

doi: 10.1038/s41408-025-01253-5

Multiple Myeloma (MM)

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM

Leukemia

Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients

Blood Cancer J

Alsugair A, Gauto Mariotti E, Alhousani MM, Fathima S, Yousuf M, Bolarinwa A, Foran J, Mangaonkar AA, Litzow M, Murthy H, Sproat L, Palmer J, Matin A, Ayala E, Slack J, Porrata L, Iqbal M, Khera N, Punwani N, Kenderian S, Chhabra S, Hogan WJ, Shah MV, Alkhateeb HB, Gangat N, Patnaik M, Tefferi A

doi: 10.1038/s41408-025-01359-w

Multiple Myeloma (MM)

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial

Lancet Haematol

Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, de la Calle VG, Oriol A, Ocio EM, Rosiñol L, Montes YG, Bargay J, García MEG, Lakhwani S, Payer AR, Suarez-Cabrera A, Blanchard MJ, Garzón S, Montero FC, Cabañas V, de Oteyza JP, Gironella M, Martinez-Lopez J, Casasús AIT, Delgado-Beltrán MP, Prieto E, Lahuerta JJ, Bladé J, San-Miguel J

doi: 10.1016/S2352-3026(25)00143-7

Related content

The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients

Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM